Articles by Laura Litwin
Clarity Pharmaceuticals announced that the first two participants in Co-PSMA have been dosed with its proprietary medication.
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
A recent study explored the impact of widely-used bladder cancer treatments on prevention, recurrence, and progression.
The study explored how a micrometric substaging system for bladder cancer could improve the predictiveness of recurrence.
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.